Deborah Collyar

5.3k total citations · 3 hit papers
69 papers, 3.2k citations indexed

About

Deborah Collyar is a scholar working on Cancer Research, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Deborah Collyar has authored 69 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Cancer Research, 25 papers in Oncology and 24 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Deborah Collyar's work include Ethics in Clinical Research (21 papers), Breast Cancer Treatment Studies (21 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Deborah Collyar is often cited by papers focused on Ethics in Clinical Research (21 papers), Breast Cancer Treatment Studies (21 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Deborah Collyar collaborates with scholars based in United States, United Kingdom and Canada. Deborah Collyar's co-authors include Robert C. Bast, Nicole M. Kuderer, Catherine Van Poznak, Fabrice André, Nofisat Ismaila, Minetta C. Liu, Eric P. Winer, Robert Mennel, Rowan T. Chlebowski and Lyndsay N. Harris and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Deborah Collyar

61 papers receiving 3.1k citations

Hit Papers

Impact of the Addition of Carboplatin and/or Bevacizumab ... 2014 2026 2018 2022 2014 2016 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
  2. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    2016 576 citations Nofisat Ismaila, Fabrice André et al. Journal of Clinical Oncology profile →
  3. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
    2024 64 citations Leisha A. Emens, Pedro Romero et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Collyar United States 22 1.7k 1.7k 682 530 477 69 3.2k
Rachel A. Freedman United States 32 1.5k 0.9× 2.4k 1.4× 535 0.8× 822 1.6× 312 0.7× 186 4.0k
Ismail Jatoi United States 33 1.9k 1.1× 2.4k 1.4× 1.1k 1.6× 449 0.8× 648 1.4× 141 4.5k
Melissa E. Hughes United States 30 2.0k 1.1× 2.2k 1.3× 404 0.6× 758 1.4× 462 1.0× 103 3.5k
Abenaa M. Brewster United States 32 1.5k 0.9× 2.2k 1.3× 706 1.0× 408 0.8× 862 1.8× 114 3.8k
Simon Cawthorn United Kingdom 23 1.3k 0.7× 1.7k 1.0× 1.5k 2.2× 495 0.9× 305 0.6× 54 3.6k
Marjanka K. Schmidt Netherlands 42 2.0k 1.2× 2.1k 1.2× 1.4k 2.1× 484 0.9× 1.3k 2.8× 160 4.8k
Karen Gelmon Canada 18 1.9k 1.1× 2.1k 1.2× 1.0k 1.5× 705 1.3× 673 1.4× 29 4.2k
K Holli Finland 28 1.3k 0.8× 1.8k 1.0× 772 1.1× 380 0.7× 778 1.6× 47 3.0k
Jeffrey S. Abrams United States 33 1.7k 1.0× 2.2k 1.3× 1.3k 1.8× 811 1.5× 494 1.0× 104 4.4k
Margaret Kemeny United States 23 862 0.5× 1.4k 0.8× 314 0.5× 494 0.9× 293 0.6× 71 2.7k

Countries citing papers authored by Deborah Collyar

Since Specialization
Citations

This map shows the geographic impact of Deborah Collyar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Collyar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Collyar more than expected).

Fields of papers citing papers by Deborah Collyar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Collyar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Collyar. The network helps show where Deborah Collyar may publish in the future.

Co-authorship network of co-authors of Deborah Collyar

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Collyar. A scholar is included among the top collaborators of Deborah Collyar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Collyar. Deborah Collyar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Minter, Daniel J., Karen D. Barton, Lesley A. Skalla, et al.. (2025). A Systematic Review of Health-Related Quality-of-Life Measurement in Patients With Complicated Urinary Tract Infections. Clinical Infectious Diseases. 81(Supplement_1). S16–S23.
2.
Howard‐Anderson, Jessica, Sarah B. Doernberg, Dennis O. Dixon, et al.. (2025). Interagency Collaboration for Patient-Centered Antibacterial Drug Development. Clinical Infectious Diseases. 81(Supplement_1). S11–S15.
3.
Norman, Katherine, Emily Lydon, Karen D. Barton, et al.. (2025). A Systematic Review of Health-Related Quality-of-Life Measurement in Patients With Acute Bacterial Skin and Skin Structure Infections. Clinical Infectious Diseases. 81(Supplement_1). S24–S31.
4.
Krah, Nathan M., Katherine Norman, Karen D. Barton, et al.. (2025). A Systematic Review of Health-Related Quality-of-Life Measurement in Patients With Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases. 81(Supplement_1). S32–S39.
5.
Emens, Leisha A., Pedro Romero, Ana C. Anderson, et al.. (2024). Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Journal for ImmunoTherapy of Cancer. 12(6). e009063–e009063. 64 indexed citations breakdown →
6.
7.
Pothuri, Bhavana, Premal H. Thaker, Rosa María Ortiz Espinosa, et al.. (2024). Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel. International Journal of Gynecological Cancer. 35(6). 101875–101875. 4 indexed citations
8.
Ozanne, Elissa M., Angela C. Tramontano, Thomas R. Lynch, et al.. (2024). Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25). Breast Cancer Research. 26(1). 134–134.
9.
Gopinath, Ramya, Daniel B. Rubin, Deborah Collyar, et al.. (2023). Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases. 77(4). 649–656. 8 indexed citations
10.
Collyar, Deborah, et al.. (2023). Aiding the Adoption of Master Protocols by Optimizing Patient Engagement. Therapeutic Innovation & Regulatory Science. 57(6). 1136–1147. 1 indexed citations
11.
Wale, Janet, et al.. (2022). Can We Afford to Exclude Patients Throughout Health Technology Assessment?. SHILAP Revista de lepidopterología. 3. 796344–796344. 6 indexed citations
12.
Collyar, Deborah, et al.. (2021). The Importance and Value of Engaging Patients in Cancer Research. Future Oncology. 17(28). 3663–3666. 2 indexed citations
13.
Engelhardt, Ellen G., Frederieke van Duijnhoven, Maartje van Seijen, et al.. (2020). The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. The Breast. 50. 95–103. 2 indexed citations
14.
O’Leary, Catina, et al.. (2020). How Health Literacy Can Enhance the Design and Conduct of Clinical Trials from Consent to Conclusion. Studies in health technology and informatics. 269. 275–284. 1 indexed citations
15.
André, Fabrice, Nofisat Ismaila, N. Lynn Henry, et al.. (2019). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx. Journal of Clinical Oncology. 37(22). 1956–1964. 151 indexed citations
16.
Hwang, E. Shelley, Terry Hyslop, Thomas Lynch, et al.. (2019). The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 9(3). e026797–e026797. 190 indexed citations
17.
Amanatullah, Derek F., John Tamaresis, Pauline Chu, et al.. (2017). Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells. Breast Cancer Research. 19(1). 121–121. 21 indexed citations
18.
Holland, Thomas L, Diane Bloom, Jamie Roberts, et al.. (2016). Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis. BMJ Open. 6(11). e013561–e013561. 4 indexed citations
19.
Bellavance, Emily, Jeffrey Peppercorn, Shari S. Kronsberg, et al.. (2016). Surgeons’ Perspectives of Contralateral Prophylactic Mastectomy. Annals of Surgical Oncology. 23(9). 2779–2787. 27 indexed citations
20.
Sikov, William M., Donald A. Berry, Charles M. Perou, et al.. (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 33(1). 13–21. 650 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel A. Freedman Breakdown of academic impact, for papers by Ismail Jatoi Breakdown of academic impact, for papers by Melissa E. Hughes Breakdown of academic impact, for papers by Abenaa M. Brewster Breakdown of academic impact, for papers by Simon Cawthorn Breakdown of academic impact, for papers by Marjanka K. Schmidt Breakdown of academic impact, for papers by Karen Gelmon Breakdown of academic impact, for papers by K Holli Breakdown of academic impact, for papers by Jeffrey S. Abrams Breakdown of academic impact, for papers by Margaret Kemeny
Rankless by CCL
2026